BioSpace News Archive

Recursion announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration.

Quanta Therapeutics today announced progress across its pipeline of KRAS-directed drug candidates, including U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance for QTX3034, a multi-KRAS inhibitor with G12D-preferring activity (G12D+ multi-KRAS), enabling the initiation of a Phase 1 clinical trial in the first quarter of 2024.

Avanos Medical, Inc. reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for 2024.

The Max Foundation (Max), a leading global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients globally today announced Eli Lilly and Company will provide free of charge access to Verzenio® (abemaciclib) for the treatment of HR-positive, HER2-negative ABC for patients in Kenya.

Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation.

Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.

VolitionRx Limited, a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.

Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced that it has filed the final module in the Pre-Market Approval application with the U.S. Food and Drug Administration for its investigational P-15 Peptide Enhanced Bone Graft.

Cognition Therapeutics, Inc. today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.

Sensei Biotherapeutics, Inc. today provided corporate updates on its research and development programs and upcoming milestones.